Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients

• US 10,150,792 B2
• Filed: 11/08/2010
• Issued: 12/11/2018
• Est. Priority Date: 11/08/2010
• Status: Active Grant

• Current Assignee: Synthonics Incorporated (Synthonics Technologies, Inc.)
• Original Assignee: Synthonics Incorporated (Synthonics Technologies, Inc.)
• Inventors: Price, John D., Piccariello, Thomas, Oberlender, Robert A., Mulhare, Michaela E., Palmer, Scott B.
• Primary Examiner(s): Tran, My-Chau T.
• Application Number:
  US12/941,599
• Publication Number:
  US 20120115823A1
• Time in Patent Office: 2,955 Days
• Field of Search: 514166
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/14 of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: C07C 229/76 Metal complexes of amino carboxylic acids
• CPC Class Codes: C07F 9/005 Compounds of elements of Group 5 of the Periodic Table without metal-carbon linkages
• CPC Class Codes: C07H 23/00 Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12 esters with inorganic acids C07H11/00; metal salts, see parent compounds
• CPC Class Codes: C08B 37/003 Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
• CPC Class Codes: C08B 37/0084 Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates

Abstract

Bismuth-containing compounds include bismuth and a biologically active agent coordinated to the bismuth. The biologically active agent includes at least one heteroatom configured for coordination with the bismuth. Coordination polymers include a polymer matrix that contains a bismuth-containing compound. Methods for modulating a pharmacokinetic property of a biologically active agent include coordinating the biologically active agent to bismuth to form a bismuth-containing compound, and administering the bismuth-containing compound orally to a patient. Methods for treating Parkinson'"'"'s disease, methods for treating hypothyroidism, methods for treating ulcerative colitis, and methods for treating cancer each include administering a bismuth-containing compound to a patient.

Claims

1. A compound comprising:

bismuth and

a biologically active agent coordinated to the bismuth;

wherein the biologically active agent comprises at least one heteroatom configured for coordination with the bismuth;

wherein the biologically active agent is levodopa and wherein the compound is selected from Bi(O)(levodopa) and Bi(O)(levodopa)₃.

2. The compound of claim 1 wherein the biologically active agent and the bismuth are coordinated through a single point of attachment.

3. The invention compound of claim 1 wherein the biologically active agent and the bismuth are coordinated through multiple points of attachment.

4. The compound of claim 1 wherein the compound further comprises an adjuvant coordinated to the bismuth.

5. The compound of claim 1 wherein a pharmacokinetic property of the biologically active agent released from the compound is modulated relative to that of the biologically active agent in an uncoordinated state.

6. The compound of claim 1 wherein the compound further comprises an adjuvant selected from the group consisting of lipids, carbohydrates, amino acids, bioadhesive polymers, peptides, bile acids, and combinations thereof.

7. The compound of claim 6 wherein the adjuvant comprises a carbohydrate.

8. The compound of claim 1 further comprising an adjuvant which is ascorbic acid.

9. The compound of claim 6 wherein the adjuvant is selected from the group consisting of arginine, glycine, leucine, and combinations thereof.

10. The compound of claim 6 wherein the adjuvant is selected from the group consisting of citric acid, carnosine, ferulic acid, alginic acid, sodium alginate, chitosan, chitin, polyacrylic acids, pectin, pullulan, hydroxypropylmethylcellulose, and combinations thereof.

11. The compound of claim 1, wherein the compound is Bi(O)(levodopa).

12. The compound of claim 1, wherein the amount of bismuth in the compound is from about 25% to about 50%.

13. The compound of claim 1, wherein the compound is insoluble in water.

14. The compound of claim 1 made by a process comprising:

a) providing a solvent comprising water to a reaction chamber;

b) adding an amount of levodopa to the reaction chamber;

c) adding an amount of a source of bismuth to the reaction chamber; and

d) isolating the compound as a solid precipitant.

15. A method of manufacturing a bismuth-containing compound comprising levodopa, carbidopa and combinations thereof comprising:

a) providing a solvent comprising water to a reaction chamber;

b) adding an amount of levodopa or carbidopa or a mixture thereof to the reaction chamber;

c) adding an amount of a source of bismuth to the reaction chamber; and

d) isolating the compound as a solid precipitant.

16. A bismuth-containing compound made by the method of claim 15.